Logistics MINDACT
Mook, Eur J Canc
2009
70 gene discovery
van ‘t Veer Nature 2002,
van de Vijver NEJM, 2002
MammaPrint available to market - 2004
Glas BMC Genomics, 2006
Delahaye Pers. Med 2013
Independent validation: TRANSBIG
Buyse JNCI 2006
RASTER Study
Bueno – de Mesquita, Lancet Oncol 2007
Drukker, Int. Journal of Canc 2013
Pilot MINDACT
1
st
800 patients
Rutgers, Eur J Cancer 2011
MINDACT Results
Primary Endpoint analysis
NEJM, august 2016
Agendia founded –July 2003
MammaPrint
•
Regulatory
•
Reimbursement
•
Guidelines
•
Adoption
Desarrollo de la evidencia clínica de
MammaPrint
Validada en > de 12.000 pacientes
•
Todos los grupos de edad
•
Tumores primarios pequeños
•
N0-N1 (1-3)
•
ER +/-
•
HER2 +/-
•
Fresco y Parafina
